**Patient Discharge Summary**

**Hospital:** Metropolitan Endocrinology Unit  
**Admission Date:** September 15, 2023  
**Discharge Date:** September 25, 2023  
**Consulting Physician:** Dr. Jane Doe, Endocrinologist  

**Patient Details:**  
- **Name:** John Smith  
- **Age:** 58  
- **Gender:** Male  
- **MRN:** 0021548963  

**Diagnosis:**  
Primary Diagnosis: Type 2 Diabetes Mellitus  
Secondary Diagnoses: Hypertension, Dyslipidemia  

**Hospital Course and Treatment:**  
Mr. John Smith was admitted to the Metropolitan Endocrinology Unit on September 15, 2023, with symptoms of polyuria, polydipsia, and unintentional weight loss over the past 3 months. His initial laboratory tests revealed a fasting plasma glucose (FPG) level of 240 mg/dL and a glycosylated hemoglobin (HbA1C) level of 9.2%, confirming the diagnosis of type 2 diabetes mellitus. His blood pressure on admission was 145/90 mmHg, and his lipid profile showed elevated LDL cholesterol levels.

During his hospital stay, Mr. Smith underwent an oral glucose tolerance test (OGTT), which further affirmed the diabetes diagnosis. He was started on a comprehensive diabetes management plan, including dietary changes, exercise, and medication.

**Medications Prescribed at Discharge:**  
1. **Metformin:** 500 mg twice daily, to be taken with meals. The dose may be adjusted based on Mr. Smith's response and tolerability, with a maximum dose of 2000 mg daily.
2. **Semaglutide (GLP-1 receptor agonist):** Initiated at 0.25 mg once weekly for 4 weeks, increasing to 0.5 mg once weekly thereafter. This medication is for glycemic control and to aid in weight loss.
3. **Lisinopril (for hypertension):** 10 mg once daily to manage his blood pressure.
4. **Atorvastatin (for dyslipidemia):** 20 mg once daily at bedtime to manage his cholesterol levels.

**Patient Education:**  
Mr. Smith received detailed education on the management of type 2 diabetes, including the importance of monitoring his blood glucose levels, recognizing symptoms of hypoglycemia and hyperglycemia, and understanding the potential complications of diabetes. He was counseled on dietary recommendations focusing on whole foods and high-quality carbohydrates and the need for regular physical activity, including at least 150 minutes of aerobic exercise per week.

He was also instructed on the correct use of his medications, including dose adjustments for Semaglutide based on his response and tolerability. The importance of regular follow-up visits with his healthcare providers was emphasized, along with the need for regular screening for diabetic complications.

**Follow-Up Care:**  
- **Endocrinology Outpatient Clinic:** Appointment scheduled for October 10, 2023, with Dr. Jane Doe for medication review and adjustment as necessary.
- **Dietitian Consultation:** Appointment scheduled for October 17, 2023, to review dietary plan and progress.
- **Diabetes Education Session:** Scheduled for October 24, 2023, focusing on advanced carbohydrate counting and insulin dose adjustment.
- **Podiatry:** Referral made for annual foot examination due to diabetes.

**Vaccinations Recommended:**  
Mr. Smith was advised to receive vaccinations against Streptococcus pneumoniae, influenza virus, hepatitis B, varicella, and SARS-CoV-2 as per the guidelines for patients with diabetes.

**Discharge Instructions:**  
Mr. Smith was advised to monitor his blood glucose levels as instructed, adhere to his medication regimen, follow the dietary and exercise recommendations, and attend all scheduled follow-up appointments. He was educated on the signs of potential complications and instructed to seek immediate medical attention if he experiences symptoms of severe hypoglycemia, hyperglycemia, or any other concerning symptoms.

**Signature:**  
Dr. Jane Doe, MD  
Endocrinology Unit  
Metropolitan Hospital